Tandon Vishal R, Sharma Sudhaa, Mahajan Shagun, Mahajan Annil, Khajuria Vijay, Gillani Zahid
Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India.
Department of Obstetrics and Gynaecology, Government Medical College, Jammu, Jammu and Kashmir, India.
J Midlife Health. 2014 Jan;5(1):29-33. doi: 10.4103/0976-7800.127788.
The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP).
A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/compliance rates of most commonly prescribed daily alendronate (ALN), weekly risedronate (RIS) and monthly ibandronate (IBN) BP regimens.
Nearly 40% was the 1 year adherence rate with BP and 41.33% of non-compliance. Whereas, 8.66% was interrupted compliance rate and 6% switched over to other anti-osteoporotic treatment. The three treatment arm did not vary significantly. However, numerically maximum adherence rate of 56% was recorded in monthly BP regimen followed by weekly (36%) and daily regimen (32%). Medication possession rate confirmed on a follow-up visit was maximum with monthly regimen as 84.61% followed by daily (62.5%) and weekly (61.11%) respectively. Average time in days for non-adherence was 48, 56 and 92 day with daily ALN, weekly RIS and monthly IBN regimen respectively. Age, mean age at menopause, demographical profile failed to influence the adherence. Concomitant treatment for co-morbid condition (57.14%), unawareness about osteoporosis (OP) (50%), cost of treatment (45.33%), belief that drugs is for their general disability (39.28%), physician's failure to stress the need and necessary calcium + vitamin D daily requirement (23.80%) each were the most prevalent factors responsible for non-adherence. Intolerance and adverse drug reactions were responsible for only 13.09% and 11.90% of non-adherence.
Treatment compliance is poor with daily ALN, weekly RIS and monthly IBN regimen along with calcium and vitamin D3 in Indian paramedical workers suffering OP.
以下研究的目的是评估绝经后骨质疏松症患者对不同双膦酸盐（BP）治疗方案的依从性和顺应性。
进行了一项为期1年的前瞻性观察性随机对照研究，以评估最常用的每日阿仑膦酸钠（ALN）、每周利塞膦酸钠（RIS）和每月伊班膦酸钠（IBN）BP治疗方案的依从性/顺应性率。
BP的1年依从率约为40%，不依从率为41.33%。而中断依从率为8.66%，6%转而接受其他抗骨质疏松治疗。三个治疗组之间无显著差异。然而，按数字计算，每月BP治疗方案的依从率最高，为56%，其次是每周（36%）和每日治疗方案（32%）。随访时确认的药物持有率以每月治疗方案最高，为84.61%，其次是每日（62.5%）和每周（61.11%）。每日服用ALN、每周服用RIS和每月服用IBN治疗方案的平均不依从天数分别为48天、56天和92天。年龄、绝经平均年龄、人口统计学特征均未影响依从性。合并症的伴随治疗（57.14%）、对骨质疏松症（OP）的不了解（50%）、治疗费用（45.33%）、认为药物是用于治疗其一般残疾的观念（39.28%）、医生未强调必要性以及每日所需的钙+维生素D（23.80%），这些都是导致不依从的最常见因素。不耐受和药物不良反应仅占不依从情况的13.09%和11.90%。
在患有OP的印度辅助医疗工作者中，每日服用ALN、每周服用RIS和每月服用IBN治疗方案以及补充钙和维生素D3的治疗依从性较差。
